199 related articles for article (PubMed ID: 24290218)
1. Novel treatment options for Waldenström macroglobulinemia.
Leblebjian H; Agarwal A; Ghobrial I
Clin Lymphoma Myeloma Leuk; 2013 Sep; 13 Suppl 2(0 2):S310-6. PubMed ID: 24290218
[TBL] [Abstract][Full Text] [Related]
2. Waldenstrom macroglobulinemia.
Leleu X; Roccaro AM; Moreau AS; Dupire S; Robu D; Gay J; Hatjiharissi E; Burwik N; Ghobrial IM
Cancer Lett; 2008 Oct; 270(1):95-107. PubMed ID: 18555588
[TBL] [Abstract][Full Text] [Related]
3. Waldenström Macroglobulinemia: Review of Pathogenesis and Management.
Yun S; Johnson AC; Okolo ON; Arnold SJ; McBride A; Zhang L; Baz RC; Anwer F
Clin Lymphoma Myeloma Leuk; 2017 May; 17(5):252-262. PubMed ID: 28366781
[TBL] [Abstract][Full Text] [Related]
4. Update on therapeutic options in Waldenström macroglobulinemia.
Leleu X; Gay J; Roccaro AM; Moreau AS; Poulain S; Dulery R; Champs BB; Robu D; Ghobrial IM
Eur J Haematol; 2009 Jan; 82(1):1-12. PubMed ID: 19087134
[TBL] [Abstract][Full Text] [Related]
5. Waldenström macroglobulinemia: a review of pathogenesis, current treatment, and future prospects.
Ghafoor B; Masthan SS; Hameed M; Akhtar HH; Khalid A; Ghafoor S; Allah HM; Arshad MM; Iqbal I; Iftikhar A; Husnain M; Anwer F
Ann Hematol; 2024 Jun; 103(6):1859-1876. PubMed ID: 37414960
[TBL] [Abstract][Full Text] [Related]
6. Novel agents in Waldenström macroglobulinemia.
Issa GC; Ghobrial IM; Roccaro AM
Clin Investig (Lond); 2011; 1(6):815-824. PubMed ID: 22034589
[TBL] [Abstract][Full Text] [Related]
7. Novel agents in Waldenstrom Macroglobulinemia.
Sacco A; Leleu X; Rossi G; Ghobrial IM; Roccaro AM
Open J Hematol; 2010 May; 1():. PubMed ID: 22844582
[TBL] [Abstract][Full Text] [Related]
8. The epidemiology of Waldenström macroglobulinemia.
McMaster ML
Semin Hematol; 2023 Mar; 60(2):65-72. PubMed ID: 37099032
[TBL] [Abstract][Full Text] [Related]
9. microRNA expression in the biology, prognosis, and therapy of Waldenström macroglobulinemia.
Roccaro AM; Sacco A; Chen C; Runnels J; Leleu X; Azab F; Azab AK; Jia X; Ngo HT; Melhem MR; Burwick N; Varticovski L; Novina CD; Rollins BJ; Anderson KC; Ghobrial IM
Blood; 2009 Apr; 113(18):4391-402. PubMed ID: 19074725
[TBL] [Abstract][Full Text] [Related]
10. Advances in Treatment of Waldenström Macroglobulinemia.
Durot E; Tomowiak C
Curr Oncol Rep; 2023 Nov; 25(11):1375-1386. PubMed ID: 37855849
[TBL] [Abstract][Full Text] [Related]
11. A SCID-hu in vivo model of human Waldenström macroglobulinemia.
Tassone P; Neri P; Kutok JL; Tournilhac O; Santos DD; Hatjiharissi E; Munshi V; Venuta S; Anderson KC; Treon SP; Munshi NC
Blood; 2005 Aug; 106(4):1341-5. PubMed ID: 15886318
[TBL] [Abstract][Full Text] [Related]
12. Waldenström macroglobulinemia.
Ghobrial IM; Witzig TE
Curr Treat Options Oncol; 2004 Jun; 5(3):239-47. PubMed ID: 15115652
[TBL] [Abstract][Full Text] [Related]
13. New Therapeutic Approaches for Waldenstrom Macroglobulinemia.
Stedman J; Roccaro A; Leleu X; Ghobrial IM
Drugs Future; 2010 Jan; 35(1):53-58. PubMed ID: 21869855
[TBL] [Abstract][Full Text] [Related]
14. Waldenström Macroglobulinemia/Lymphoplasmacytic Lymphoma, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology.
Kumar SK; Callander NS; Adekola K; Anderson LD; Baljevic M; Baz R; Campagnaro E; Castillo JJ; Costello C; D'Angelo C; Derman B; Devarakonda S; Elsedawy N; Garfall A; Godby K; Hillengass J; Holmberg L; Htut M; Huff CA; Hultcrantz M; Kang Y; Larson S; Lee H; Liedtke M; Martin T; Omel J; Robinson T; Rosenberg A; Sborov D; Schroeder MA; Sherbenou D; Suvannasankha A; Valent J; Varshavsky-Yanovsky AN; Snedeker J; Kumar R
J Natl Compr Canc Netw; 2024 Jan; 22(1D):e240001. PubMed ID: 38244272
[TBL] [Abstract][Full Text] [Related]
15. New developments in the management of Waldenström macroglobulinemia.
Abeykoon JP; Yanamandra U; Kapoor P
Cancer Manag Res; 2017; 9():73-83. PubMed ID: 28331368
[TBL] [Abstract][Full Text] [Related]
16. Dysfunctions of innate and adaptive immune tumor microenvironment in Waldenström macroglobulinemia.
Cholujova D; Beke G; Hunter ZR; Hideshima T; Flores L; Zeleznikova T; Harrachova D; Klucar L; Leiba M; Drgona L; Treon SP; Kastritis E; Dorfman DM; Anderson KC; Jakubikova J
Int J Cancer; 2023 May; 152(9):1947-1963. PubMed ID: 36533670
[TBL] [Abstract][Full Text] [Related]
17. Novel Agents in Waldenström Macroglobulinemia.
Sarosiek S; Castillo JJ
Hematol Oncol Clin North Am; 2023 Aug; 37(4):751-760. PubMed ID: 37198054
[TBL] [Abstract][Full Text] [Related]
18. TLR-mediated activation of Waldenström macroglobulinemia B cells reveals an uncoupling from plasma cell differentiation.
Shrimpton J; Care MA; Carmichael J; Walker K; Evans P; Evans C; de Tute R; Owen R; Tooze RM; Doody GM
Blood Adv; 2020 Jun; 4(12):2821-2836. PubMed ID: 32574366
[TBL] [Abstract][Full Text] [Related]
19. Biomarkers of Progression and Risk Stratification in Asymptomatic Waldenström Macroglobulinemia.
Bustoros M; Gribbin C; Castillo JJ; Furman R
Hematol Oncol Clin North Am; 2023 Aug; 37(4S):e1-e13. PubMed ID: 37574332
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
